Medicines Co. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
?
W******* i* V********
?
L*********** I********** f** d** n******* J****
?
U****************
Kontra
?
A****************
?
M************
?
M****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 0,06 % | -14,38 % | -4,98 % | -23,98 % | -31,19 % | -29,67 % | -44,90 % |
| Opko Health Inc. | 1,67 % | -0,50 % | -0,82 % | -15,51 % | -9,19 % | -21,23 % | -70,14 % |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -1,11 % | 0,00 % | -2,70 % | -1,64 % | -8,16 % | -38,36 % | -13,46 % |
Kommentare
News
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca (NASDAQ:ERAS), a developer of therapies for RAS/MAPK pathway-driven cancers, closed at $9.90, down 48% on Tuesday. Shares fell after the company disclosed a patient death from pneumonitis in
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems
If a stock has a market cap of nearly $30 billion, you would probably expect its business to be well developed, generating significant revenue, and likely profitable. But there's one stock trading
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated